

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11) Publication number:

**0 209 06
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86109329.2

(51) Int. Cl.: **C 07 C 59/42, C 07 C 69/732,
A 61 K 31/20, A 61 K 31/23**

(22) Date of filing: 08.07.86

(30) Priority: 11.07.85 CA 486737


(71) Applicant: Canadian Patents & Development Ltd.,
275 Slater Street, Ottawa Ontario, K1P 5H9 (CA)(43) Date of publication of application: 21.01.87
Bulletin 87/4(72) Inventor: Buchanan, Michael R., 417 Lake Promenade,
Toronto Ontario M8W 1Z3 (CA)

(84) Designated Contracting States: BE DE FR GB NL SE

(74) Representative: Goddar, Heinz J., Dr. et al, FORRESTER
& BOHMERT Widenmayerstrasse 4/I,
D-8000 München 22 (DE)

(54) Chemorepellant compound.

(57) A chemorepellant compound is disclosed having a general formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof. A preferred form of the compound where R_1 is hydrogen and R_2 is hydrogen is made by incubating linoleic acid with soyabean lipoxygenase or with cytosol associated and thelial cell derived lipoxygenase. The chemorepellant compound can be bound to a prosthetic surface via an intermediate linking species such as a protein and studies have shown that platelet adhesion onto in the vicinity of a thrombogenic surface is greatly reduced in comparison to non-chemorepellant coated surfaces.

ACTORUM AG

CHEMOREPELLANT COMPOUND

The present invention relates to a chemorepellant compound for attachment to a prosthetic surface for use in human and animal cardiovascular systems to provide a biocompatible surface with reduced thrombogenicity. In particular, the invention also relates to a method of manufacturing the chemorepellant compound, to a method of attaching the compound to a prosthetic surface and to a method of use of the compound in vivo.

For many years, numerous investigators have tried to develop a suitable biocompatible surface for prosthetic materials when used as a replacement material within the cardiovascular system. This has been difficult to achieve because a wide variety of prosthetic substances are necessary such as, flexible polymers and rigid materials since these materials are selected not only for their desirable surface characteristics but also for their physical properties. However, no artificial surface currently available is wholly compatible with blood and despite considerable research no artificial surface has been found which is as inert towards blood as the endothelial surface of blood vessels. In particular, all artificial surfaces tend, to some extent, to activate blood coagulation, and to attract platelets and leukocytes, although some materials appear to be less reactive than others. Some specific undesirable properties of biomaterials have been identified. For example, it has been found that highly charged surfaces or surfaces with a rough

2
texture are reactive and should be avoided. It has been found that very smooth prosthetic surfaces are desirable because it appears that surface irregularities may enhance thrombus formation, probably by producing local disturbances and flow that favour cell adhesion and promote fibrin formation. Irregular surfaces may also be prone to retention of small air bubbles that can serve as nidus for thrombus formation.

The use of prosthetic surfaces that contact blood produces a highly complex situation with respect to the blood components. This situation is brought about by surface contact and alteration of certain plasma proteins as well as by adhesional blood cells. In addition, the mechanical effects of elevated shear stress can alter plasma proteins in blood cells in undesirable ways. For example, blood pumps and heart valves can mechanically damage cells and denature plasma proteins. Consequently, blood anticoagulants have been used in renal dialysis, prosthetic heart valve implantation, extracorporeal oxygenation and blood detoxification by extracorporeal sorption devices.

Exposure of blood to artificial surfaces can lead to several different consequences, the principal ones of which are thrombosis and embolization. Thrombosis occurs when clots develop on an artificial surface and impede the function of the artificial organ such as a prosthetic heart valve or vascular graft. To a certain extent the haemodynamic effects dictate the nature of thrombus formation. For example, in areas of slow blood flow such as the reservoir of pump-oxygenator a red fibrin clot may develop whereas in the regions of high fluid shear

rates, such as an arterial bypass graft platelet accumulation may be more prominent. Embolization is the event when a thrombus formed in one site of the cardio vascular is swept downstream to resituate in a vessel or organ. For example, in cerebral embolization a thrombus formed on a prosthetic heart valve may embolize and cause a cause of strokes. Clearly, this is a very serious situation and as such thrombus formation and subsequent embolization can result in serious injury and even death.

It is therefore very desirable that a prosthetic surface should minimize thrombogenicity and subsequent embolization of thrombus formation. In this regard, it is important that the prosthetic surface attempt to simulate the biocompatibility of the endothelium or the luminal lining of healthy blood vessels which do not promote blood clotting or the adherence of circulatory blood cells under normal circumstances. However, it will be appreciated that following injury the endothelial surface becomes the site of a complex reparative reaction following coagulation, fibrinolysis and platelet and leukocyte and blood-cell vessel wall interactions.

At present, there is no artificial substance which is comparable to the endothelium and freed of thrombotic effects. Studies have indicated that there may be an active role for products of endothelial metabolism in inhibiting platelet activity at the vessel wall. In this regard, some investigators have attached biologically active molecules to solid materials in an effort to produce "actively" antithrombogenic materials. For example, heparin coated prosthetic surfaces have been widely

used. However subsequent studies have shown that heparin will leach from the surface and generally form a film of anticoagulative blood at the interface which is responsible for reduced thrombus formation rather than from any intrinsic properties of the surface itself. Clinically heparinized prosthetic surfaces have had mixed success and continues to be a problem in understanding how heparin coated surfaces affect the thromboresistance. In fact, heparin has been shown to induce platelet aggregation and enhance platelet responses to other stimuli under some circumstances.

Other materials have been used to coat prosthetic surfaces prior to contacting with blood and there have been claims for reduced reactivity with platelets. For example, covalently bound albumin has been used to coat artificial materials and although some early results were encouraging long term thromboresistance has not been obtained. More active inhibitors of platelet adhesion such as prostaglandin and aspirin have also been attached to some polymers, however, results have been inconsistent and long-term assessment of in-vitro or in-vivo thromboresistance has not been reported.

It should be understood that for successful function of prosthetic surfaces in the cardiovascular system total freedom from thrombosis is not essential. For example, an arterial prosthesis made from knitted dacron invariably accumulates an inner layer of fibrin-platelet thrombus and is gradually invaded by fibroblasts and capillary buds and then coated by a layer neoendothelium. However, the graft functions well to transport blood provided its diameter is sufficiently large to obviate


occlusion of the lining by thrombus formation. The same criteria applies to the rigid frame of prosthetic heart valves which can also tolerate a thin layer of adherent thrombus. However, it should also be appreciated that the success of such devices is contingent on the fact that the thrombus does not form or impinge on moving components or break off form emboli and subsequently block vessels. For this reason fibrin-coated surfaces have been used to insure against detachment of the thrombotic coat. It has been found that endothelium will grow from the host vessel over the interior of such a device to provide an endothelial layer facing the blood to stabilize the situation. It will be appreciated however that results with such systems are uncertain and it is very desirable to provide a prosthetic surface which is as inert as possible to blood and which minimizes thrombogenicity which would greatly assist in the preventing of clotting and subsequent embolization from detached clots.

It is an object of the present invention to provide an anti-thrombogenic or chemorepellant compound for attachment to a prosthetic surface for location in the cardiovascular system to provide improved biocompatibility on the surface over existing biocompatible materials.

It is also an object of the invention to provide a method of manufacturing such a chemorepellant compound and for providing a method of use of the compound.


Accordingly, there is provided a chemorepellant

compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof.

10 According to another aspect of the invention there is provided a method of manufacturing a chemorepellant compound having the structural formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof, said

20 method comprising the steps of


providing a supply of endothelial cells, incubating said supply of endothelial cells with linoleic acid in a media for a predetermined incubation period or with cytosol associated endothelial cell derived lipxygenase.

25 According to yet another aspect of the present invention there is provided a method of rendering a prosthetic surface thromboresistant comprising the steps of:

coating said prosthetic surface with a chemorepellant


ic surface

then further coating said coated prosthetic surface with a chemorepellant compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and
10 R_2 is H or an appropriate hydroxyl protecting group, and
pharmaceutically acceptable salts and esters thereof to provide
a thromboresistant prosthetic surface.


According to yet another aspect of the present invention there is provided a thromboresistant surface for use in a vascular system, consisting of a prosthetic material, an intermediate species linked to said prosthetic material and a chemorepellant compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and
25 pharmaceutically acceptable salts and esters thereof in a pharmaceutically effective amount attached to said intermediate species, said chemorepellant compound forming an outer surface for contacting blood.

According to yet further aspect of the invention there is provided a thromboresistant surface for use in a vascular system, said thromboresistant surface having a prosthetic base material, a protein linked to said base material to provide a binding substrate, and a chemorepellant compound having the formula L-13 hydroxy-cis-9, trans-11 octadecadienoic acid, and the structure:

10




said chemorepellant compound being linked to said binding substrate and providing a blood-contactable thromboresistant surface.

15

In a preferred embodiment of the invention the chemorepellant compound has formula 13 - OH - 18:2 and the structural formula L-13 hydroxy-cis-9, trans-11 octadecadienoic acid, and the structure:

20




Preferably the compound is made by reacting endothelial cells with linoleic acid for a predetermined period and producing significant production of metabolite cells of the order of $\ln M/10^6$ cells of culture and in a preferred method of using the compound albumin is coated onto a prosthetic surface and the

q

albumin coated surface is reacted with a pharmaceutically effective concentration of the chemorepellant compound which adheres to the albumin to provide a thromboresistant coating.

A preferred chemorepellant compound has the formula
 5 L-13 hydroxy-cis-9, trans-11 octadecadienoic acid, and the structure:



10

is used and is attached to a prosthetic surface via an intermediate binding agent which is a protein.

These and other aspects of the invention will become apparent from the following description when taken in
 15 combination with the accompanying drawings in which: -

Fig. 1 is a general structural formula of the chemorepellant compound;

Fig. 2 is a preferred structural formula of the chemorepellant compound according to a preferred method of
 20 manufacturing said chemorepellant compound;

Figs. 3a-d show reverse phase high performance liquid chromatography (HPLC) tracings of (a) standards, media, 12-HETE, 15-HETE and the chemorepellant compound (13-HODE); (b) endothelial cell extract; (c) smooth muscle extract; and
 25 fibroblast extract; and

Fig. 4 is a Gas Chromatography/Mass Spectroscopy (GC/MS) output profile of a reduced form of purified hydrogenated chemorepellant compound (13-HODE).

Fig. 5 is a graph illustrating the platelet adhesion (as a percentage of control), versus the concentration of 12-HETE, LOX PGI_2 , and 6-keto PGE_1 to ThermonoxTM plastic discs; and

5 Fig. 6 is a graph of light transmission versus time for determining the collagen induced platelet, aggregation of platelets exposed to but not adherent in discs incubated in LOX. 12-HETE, arachidonic acid (AA, PGI_2 or 6-keto PGE_1) in which the arrow indicates the addition of collagen at time zero.

10 The following description discloses the materials and methods for the manufacture of the preferred compound; the subsequent analysis and confirmation of the structure, and a method of binding the chemorepellant compound to a prosthetic surface.

15 The general formula includes a ring structure with double bonds; cis-cis 9-12 octadecadienoic acid having modified by the enzyme to 9-cis 11-trans octadecadienoic acid as shown in Fig. 2 with the OH group attached at C-13. However the Hydrogen on the carboxyl group and on the hydroxyl group can be substituted, as later described, to provide pharmaceutically acceptable salts and esters thereof, as given by the general structural formula shown in Fig. 1. The hydroperoxide bond is generally believed to be unstable in fatty acids or acid metabolites and is believed to be the reason for the chemorepellant properties.

20

25

Materials and Methods

$\text{U-}^{14}\text{C}$ -linoleic acid ($^{14}\text{C-18:2}$) and $\text{U-}^{14}\text{C}$ -arachidonic acid ($^{14}\text{C-20:4}$) were obtained for New England

11
Nuclear, Boston, MA. Soybean lipoxygenase (EC 1.13.11.12),
linoleic acid (18:2), arachidonic acid (20:4) and calcium
ionophore (A23187) were obtained from Sigma Corp., St. Louis,
MO. All cell culture materials were obtained from GIBCO, Grand
5 Island, NY. Pooled human sera were obtained from the Canadian
Red Cross, Hamilton, ONT. The sera were heat-inactivated at
56°C for 30 minutes. All culture glassware was obtained from
Costar, Cambridge, MA.

All solvents and chemicals used for this layer
10 chromatography (TLC), reverse phase high pressure liquid
chromatography (HPLC) and gas chromatography/mass spectrometry
(GC/MS), were obtained from Fisher Scientific Co., Toronto,
ONT., and Interchim, Montlucon, France. TLC was performed
using silica H plates (20x20cm x 250um) obtained from Supelco,
15 Bellefonte, PA, and Merck, Darmstadt, FRG. All glassware used
for sample preparations were silanized with 4%
dimethyldichlorosilane in toluene before use.

HPLC was performed on a NOVA-PAK C₁₈ cartridge (5mm x
10cm) compressed in a RCM-100 column. The M720 Systems
20 Controller allowed for a two-solvent gradient elution (using M45
and a M6000A pumps) and fully automated sample injector
(WISPTM). Sample detection was performed on a variable (M480)
wavelength absorbance detector at 236nm, and recorded on a 730
Data Module. All HPLC instruments were obtained from Waters
25 Scientific, Mississauga, ONT.

GC/MS was performed on a SE-54 wall-coated capillary
column (22mm x 50m) which was interfaced in a Nermag quadripolar
instrument, (Paris, France).

Cell Culture Preparations

Human umbilical vein-derived endothelial cells were cultured in vitro according to the method of Gimbrone, M.A., Shefton, E.S., and Cruise, S.A. (1978) TCA Manual 4, 813-817), with the following modifications. The cells were grown in M199 supplemented with 20% pooled human heat-inactivated sera (instead of fetal-calf serum), 100 U/ml penicillin, 100 ug/ml streptomycin, 100 ug/ml endothelial cell growth supplement, as disclosed by Maciag, T., Cerundolo, J., Ilsley, S., Kelley, P.R., and Forand, R. (1979) Proc. Natl. Acad. Sci. U.S.A. 76, 5674-5679, and grown on fibronectin-coated T25 flasks. Rat arterial smooth muscle cells (WHK-normotensive rats) were obtained from the Dept. of Anaesthesia, McMaster University and human lung fibroblasts were obtained from the Dept. of Pathology, McMaster University.

HPLC Analysis:

Endothelial cell, smooth muscle cells and fibroblasts, and their related medias, were extracted for any lipoxygenase metabolites according to the method of Borgeat, P., de Lacl s, B.F., Rabinovitch, H., Pfcard, S., Braguet, P., Hebert, J., and Lavioette, M. (1984) J. Allergy Clin. Immunol. 74, 310-315). Briefly, the cell medias were transferred to separate tubes containing an equivolume of ice-cold methanol. Then 2 ml of ice-cold methanol (75%) were added to the remaining cells which were then scraped from the T25 flask with a rubber policeman. The particulate fraction was separated from the methanol by centrifugation at 1200g for 30 minutes at -10°C. The free fatty acids in the methanol supernatant were then assayed by injecting

five hundred μ l of the fluid onto a Nova-Pak C_{18} cartridge and eluted off at a flow rate of 1.5 ml/min under 650 PSI using an acetronitrile gradient. It was qualified by measuring its absorbance at 236 nm.

5 12-HETE, 13-HODE, 15-HETE, 20:4 and 18:2 standards are described as follows: -

 20:4 and 18:2 were purified by HPLC. 13-OH-9cis, 11-trans-octadecadienoic acid (13-HODE) and 15-hydroxyeicosatetraenoic acid (15-HETE) were prepared by
10 incubating 18:2 and 20:4, respectively, with soybean lipoxygenase according to the method of Hamberg and Samuelsson; Hamberg, M.C., and Samuelsson, B. (1967) J. Biol. Chem. 242, 5329-5335). Platelet-derived 12-hydroxy-eicosatetraenoic acid (12-HETE) was prepared from 20:4 according to the method of Sun,
15 F.F. (1981) Methods of Enzymology 72, 435-442. All metabolites were purified by HPLC.

 Samples of cellular or media extracts were further purified for GC/MS analysis by HPLC or alternatively, the monohydroxy derivatives were purified by thin-layer
20 chromatography according to standard methods, disclosed by Croset, M., and Lagarde, M. (1983) Biochem. Biophys. Res. Commun. 112, 878-8830, and then derivatized for GC/MS. Briefly, the lipid extracts were transformed into methylesters by treatment with an ether saturated solution of diazomethane for
25 15 minutes at 22°C, and then transformed into trimethylsilylethers by N,O-bis(trimethylsilyl)-fluoro-acetamide treatment for 1 hour at 40°C. The derivatized extracts were then either hydrogenated or deuterated in the presence of

platinum. The derivatized extracts were then injected onto the GC column used with a temperature gradient (170-285°C, 2°/min). The MS conditions for analysis were: electron voltage, 70eV, electron multiplier, 2kV.

5 Experimental Design

Endothelial cells, smooth muscle cells or fibroblasts were incubated in serum free media \pm 2 μ M of 14 C-18:2 or 14 C-20:4 for 20 minutes, followed by stimulation for 10 minutes with \pm (unlabelled 18:2 or 20:4) \pm [calcium ionophore (A23187, 1-10 μ M), thrombin (0.1-10 Units/ml) or trypsin (0.0025-0.05%). Both the cell extractions and their media were analyzed by HPLC and GC/MS.

Results

Under HPLC, purified 13-HODE, 15-HETE and 12-HETE
15 eluted from the C_{18} column at 14.95-15.15, 15.65-15.80, and 16.85-17.20, minutes respectively as measured at 236 nm (Fig. 3a). When intact and unstimulated endothelial cells were extracted with methanol to obtain the hydroxyl derivatives of the free fatty acids, the major chemorepellant compound (LOX)
20 eluted from the C_{18} column at 14.95-15.15 minutes (Fig. 3b), consistent with 13-HODE. A similar metabolite was also detectable in the extracts from smooth muscle cell (Fig. 3c) and fibroblasts (Fig. 3d), however, the amounts produced by the latter two cell types were significantly less than that produced
25 by endothelial cells.

The structural identity of the chemorepellant compared to the purified 13-HODE was determined by running, the hydroxygenated or deuterated derivatized cell extracts under

GC/MS. Endothelial cell LOX, separated by either HPLC or by TLC, exhibited a peak retention time of 35 minutes and co-chromatographed with the hydrogenated form of 13-HODE. As best seen in Fig. 4, their mass spectra were similar with the two main fragments (M/z 173 and 315), corresponding to the breakage on both sides of the OTMS. When the derivatized extracts were subjected to deuteration instead of hydrogenation, the mass spectrum exhibited major fragments at M/z 173 and 319, (data not shown) because of four (4) extra neutrons, indicating that the initial molecule possessed two double bonds between C_1 and C_{12} . These confirmed that the chemorepellant compound with LOX was 13-OH-18:2. Further GC/MS analysis of the total monohydroxy derivatives indicated that there was no detectable 12-, 15-OH-20:0, 14- or 17-OH-22:0 metabolites. As seen in Fig. 4c, the metabolite produced by smooth muscle cells which also eluted at 15 minutes was also consistent with 13-HODE.

The amount of 13-OH-18:2 produced by unstimulated cells was 3410 ± 340 ng/ 10^6 (mean \pm SEM) for endothelial cells ($n = 15$). 1650 ± 350 ng/ 10^6 for smooth muscle cells ($n = 5$), and 500 ± 70 ng/ 10^6 for fibroblasts ($n = 5$). When cells were stimulated with thrombin, calcium ionophore (A23187) and trypsin, there were dose-dependent decreases in 13-OH-18:2 were associated with dose-related increases in a 12.5 minute HPLC peak (with A23187), a 9 minute peak (with trypsin), and no new peak with thrombin.

The structural characteristics of the chemorepellant compound shown in Fig. 2, firmly imply that its substrate is 18:2 linoleic acid and by GC/MS it has been confirmed that LOX

16
is structurally compatible with 13-HODE, and is the major
lipoxygenase metabolite produced by endothelial cells.

13-OH-18:2 was produced in significant amounts by 'unstimulated'
endothelial cells and decreased by thrombin, A23187 or trypsin

5 stimulation. The decrease in 13-OH-18:2 with a corresponding
increase in other peaks (depending upon the stimulus), suggests
that these agents caused either the stimulation of additional
metabolites at the expense of 13-OH-18:2 production, or caused
some degradation of the cell membrane including 13-OH-18:2, and

10 13-OH-18:2 was produced by endothelial cells in significantly
greater amounts than by either smooth muscle cells or
fibroblasts. These observations are consistent with the
hypothesis found in a paper by Buchanan, M.R., Butt, R.W.,
Magas, Z., Van Ryn, J., Hirsh, J. and Nazir, D.J., (July, 1985)

15 Thromb. Haemostas. In Press, which postulated that LOX
(13-OH-18:2) acts as an important thromboresistant or
'chemorepellant' factor for the vessel wall under healthy
conditions.

No other lipoxygenase-derived metabolites from 20:4 or
20 22:4 were detected. There are two possible sources of the 18:2
stores necessary for the metabolism of the chemorepellant
compound LOX; (i) the phospholipid pools, in particular
phosphatidylcholine (PC) and /or phosphatidylinositol (PI), and
(ii) the endothelial cells triglyceride pool. The first
25 possibility seems unlikely since the liberation of 18:2 from PC
requires the activation of phospholipase A₂ described in
Jimeno-Abendano, J. and Zahler, P. (1979) Biochim. Biophys. Acta
573, 266-275 which in turn, requires mobilization of calcium

described in Jesse R.L. and Franson R.C. (1979) *Biochim. Biophys. Acta* 575, 467-470. However, 13-OH-18:2 is present in the endothelial cell under basal or unstimulated conditions and at physiological calcium concentrations, two conditions under which phospholipase A₂ is not activated. In addition, thrombin, A23187 and trypsin, at concentrations which activate phospholipase A₂, did not stimulate 13-OH-18:2 production but rather resulted in a decreased production. Endothelial cell PI is also an unlikely source for 13-OH-18:2 since it is likely to be rich in 20:4 and stearic acid but not 18:2 as in other cells (Marcus, A.J. (1978) *J. Lipid Res.* 19, 783-826). It is believed that the source for the endothelial cell 18:2 is the triglyceride stores. Denning et al. (*J. Lipid Res.* 24 (1983) 993-1001) reported that there was a high turnover of fatty acids in the endothelial cell triglyceride pool, and Lagarde et al (*In Vitro* 20, (1984) 33-37) have reported that a major polyunsaturated fatty acid in endothelial cells triglycerides is 18:2. These two observations are consistent with the hypothesis that 13-OH-18:2 is derived from the substrate, 18:2, stored in triglycerides, and which is continuously produced under basal conditions, as is evidenced by the continuous triglyceride turnover.

Studies of the effectiveness of the chemorepellant compound, prior to its structural details being fully required, by binding the chemorepellant compound to albumin coated plastic discs. Thermanox^R plastic discs were incubated for 18 hours in 1% essentially fatty acid-free Tyrodes albumin at 4°C. The discs were then removed from the albumin suspension, rinsed in a

3-wash series of HBSS and incubated in increasing concentrations of LOX, 12-HETE, arachidonic acid, PGI_2 or 6-keto PGE_1 . Thirty minutes later, each disc was removed and rinsed again in a 3-wash series of HBSS and then incubated in 750ml. of ^3H -adenine-labelled platelet suspensions for 30 minutes at 37°C . Adhesion of ^3H -adenine-labelled platelets to albumin-coated discs was measured using a modification of the platelet/endothelial cell adhesion assay described by Gimbrone, M.A. and Buchanan, M.R., Endothelium, A.P. Fishman (ed). Ann NY Acad Sci 401 (1983), 171-183. In preliminary studies, it was found that 0.8 - 1.0% ^{14}C -arachidonic acid, ^3H -12-HETE and ^3H - PGI_2 , regardless of concentrations, ranging from, 10^{-9} to 10^{-3} , bound to the albumin-coated discs. A similar percentage binding characteristics for 6-keto- PGF_1 and the LOX preparation was assumed.

Platelet adhesion to the fatty acid metabolite-coated discs was then determined as described in the Gimbrone and Buchanan reference mentioned above. Also, at the end of the 30 minute incubation period, the platelets in suspension that were exposed to but not adherent on the fatty acid metabolite-coated discs were tested for collagen-induced platelet aggregation.

Results

Adhesion of aspirin-treated platelets to the Thermanox^R plastic discs coated only with essentially fatty acid-free albumin was $12,140 \pm 1,250$ platelets/ mm^2 of disc surface area ($100 \pm 10\%$; mean \pm SEM; $n = 6$, as shown). As seen in Fig. 5, when the albumin-coated discs were incubated for 30 minutes in increasing concentrations of arachidonic acid or

12-HETE, platelet adhesion was significantly increased, $p < 0.001$. In contrast, when the albumin-coated discs were incubated in increasing concentrations of LOX for 30 minutes, platelet adhesion was significantly decreased ($p < 0.001$).

- 5 Incubating the discs in PGI_2 or 6-keto PGE_1 had no effect on adhesion.

Collagen-induced aggregation of platelets exposed to but not adherent on the chemorepellant compound-, arachidonic acid-, or 12-HETE-coated discs was unaffected as best seen in
10 Fig. 6, while platelet aggregation was totally inhibited when the platelets were exposed to the PGI_2 - or 6-keto PGE_1 -coated discs.

The observations that the chemorepellant compound inhibited platelet adhesion to the discs but had no effect on
15 platelet aggregation suggests that the effect of chemorepellant compound is a direct effect on platelet adhesion at the disc surface by the chemorepellant compound coating. This is believed to be due to the hydroperoxy group (OH) at site of C-13 which is the active site for chemorepellant activity.


20 It will be appreciated that the preferred structure shown may be modified by replacing the H of the carboxyl group by the alkyl group having one to six carbon atoms and the H of the OH group may be replaced by an appropriate hydroxy protecting group. It will also be appreciated that
25 pharmaceutically acceptable salts and esters of the compound can be bound to an intermediate binding species such as albumin coated on a prosthetic surface. Also, instead of soyabean lipooxygenase, any other suitable cytosol associated endothelial

cell derived lipox yg nase can be used. For example, the Hydrogen of the carboxyl group may be replaced by Sodium, Potassium, Calcium, Magnesium or Aluminum to give pharmaceutically acceptable salts thereof. It is believed that
5 the stereochemical structure has a ring-like structure but it is also likely that a non-ring structure having the same chemical formula is possible.

The features disclosed in the foregoing description, in the claims and/or in the accompanying drawings may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:


1. A chemorepellant compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof.

2. A chemorepellant compound as claimed in claim 1 wherein R_1 is H and R_2 is H.
3. A chemorepellant compound as claimed in claim 1 wherein R_1 is a CH_3 group.
4. A chemorepellant compound as claimed in claim 1 wherein R_1 is an alkali metal ion selected from the group Sodium, Potassium, Calcium, Magnesium and Aluminum.
5. A chemorepellant compound as claimed in claim 4 wherein R_2 is H.
6. A chemorepellant compound for attachment to a prosthetic surface for minimising the thrombogenicity of said prosthetic surface, said chemorepellant compound having the

formula L-13 hydroxy-cis-9, trans-11 octadecaadienoic acid, and the structure:



7. A method of producing a chemorepellant compound claimed in claim 6 for attachment to a prosthetic surface for reducing the thrombogenicity of said prosthetic surface, said method comprising the steps of:

providing a supply of endothelial cells,

incubating said supply of endothelial cells with linoleic acid in a media for a predetermined incubation period, the linoleic acid being selected to be the precursor of said chemorepellant compound claimed in claim 6.


8. A method as claimed in claim 7 including the step of extracting said chemorepellant compound from said media.

9. A method as claimed in claim 7 or claim 8 including the step of analysing said extracted compositions to determine the composition thereof, and comparing said extraction composition analysis with a reference composition.

10. A chemorepellant compound when made by the method of claim 7.

11. A method of rendering a prosthetic surface thromboresistant, said method comprising attaching a chemorepellant compound as claimed in claim 1 to said surface via an intermediate linking species attached to the surface.
12. A method as claimed in claim 11 wherein said intermediate linking species is a protein.
13. A method as claimed in claim 12 wherein said protein is albumin.
14. A method as claimed in claim 9 wherein said chemorepellant compound is attached to said artificial surface in a pharmaceutically effective concentration to minimise thrombosis formation adjacent to said surface.
15. A method as claimed in claim 12 including incubating said albumin coated artificial surface within a pharmaceutically effective concentration of said chemorepellant compound for a predetermined period to provide a pharmaceutically effective concentration on said surface.
16. A method of rendering a prosthetic surface thromboresistant comprising the steps of:
coating said prosthetic surface with a chemorepellant binding species to form a coated prosthetic surface


then further coating said coated prosthetic surface with a chemorepellant compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof to provide a thromboresistant prosthetic surface.

17. A method as claimed in claim 16 wherein said prosthetic surface is coated with said chemorepellant binding species by incubating said prosthetic surface in a chemorepellant binding species suspension for a first predetermined period, and then further coating said coated prosthetic surface by incubating said coated surface in a suspension of said chemorepellant compound for a second predetermined period.

18. A thromboresistant surface for use in a vascular system, consisting of a prosthetic material, an intermediate species linked to said prosthetic material and a chemorepellant compound having the formula




where R_1 is H or an alkyl group in the range C_1 to C_6 , and R_2 is H or an appropriate hydroxyl protecting group, and pharmaceutically acceptable salts and esters thereof in a pharmaceutically effective amount attached to said intermediate species, said chemorepellant compound forming an outer prosthetic surface for contacting blood.

19. A prosthesis as claimed in claim 14 wherein said intermediate species is a protein.

20. A prosthesis as claimed in claim 15 wherein said protein is albumin.

21. A thromboresistant surface for use in a vascular system, said thromboresistant surface having a prosthetic base material, a protein linked to said base material to provide a binding substrate, and a chemorepellant compound having the formula L-13 hydroxy-cis-9, trans-11 octadecadrenoic acid, and the structure:




linked to said binding substrate and providing a blood-contactable thromboresistant surface.

22. A method of making a thromboresistant surface for a blood contactable prosthesis comprising the steps of:

providing a prosthetic substrate,
 attaching to said prosthetic substrate a chemorepellant
 binding species to provide a coated surface, and attaching a
 chemorepellant compound, as claimed in claim 1, in a
 pharmaceutically effective amount to said coated substrate to
 provide said thromboresistant surface.

23. A chemorepellant compound having the formula



where R_1 is H or an alkyl group in the range C_1 to C_6 , and
 R_2 is an appropriate hydroxyl protecting group, and
 pharmaceutically acceptable salts and esters thereof.

24. A chemorepellant compound as claimed in claim 23 wherein
 R_1 is H and R_2 is H.

1/5

0209066




FIG. 1




FIG. 2





FIG. 3

3/5

0209066



GC/MS profiles of (a) purified hydrogenated 13-HODE; (b) endothelial cell lipxygenase extract, 15 min peak; and, (c) smooth muscle cell extract, 15 min peak.

FIG. 4

4/5

0209066




FIG. 5

5/5

0209066




FIG. 6



European Patent
Office

EUROPEAN SEARCH REP RT

0209066

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86109329.2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	CHEMICAL ABSTRACTS, vol. 65, no. 11, November 21, 1966, Columbus, Ohio, USA W.H. TALLENT et al. "(R)-13-Hydroxy-cis-9,trans-11-octadeca_dienoic acid, the principal fatty acid from Coriaria napaleusis seed oil" column 17007, abstract-no. 17 007b-d & Tetrahedron Letters 1966 (36), 4329-34 ---	1,2,5, 6,23, 24	C 07 C 59/42 C 07 C 69/732 A 61 K 31/20 A 61 K 31/23
X	CHEMICAL ABSTRACTS, vol. 94, no. 19, May 11, 1981, Columbus, Ohio, USA M.O. FUNK et al. "The preparation and characterization of the methoxy derivatives of polyunsaturated fatty acids; stabilized product analogs of lipoxygenase catalysis" page 318, column 2, abstract-no. 152 945r & Lipids, 1980, 15(12), 1051-4 ---	1	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 07 C 59/00 C 07 C 69/00
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 06-10-1986	Examiner HOFBAUER
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EP Form 1500 (03/82)



European Patent
Office

EUROPEAN SEARCH REPORT

0209066

- 2 -
Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 86109329.2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
X	CHEMICAL ABSTRACTS, vol. 98, no. 5, January 31, 1983, Columbus, Ohio, USA K.L. MIKOLAJCZAK et al. "Effect of oat constituents on aggregation behavior of <i>Oryzaephilus surinamensis</i> " page 579, column 2, page 580, column 1, abstract-no. 33 665x & J. Agric. Food Chem. 1983, 31(1), 30-3 -----	1,3	
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 06-10-1986	Examiner HOFBAUER
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background P : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document			

EPO form 1503 03 82